[Form 4] Tenon Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Tenon Medical, Inc. (TNON) CEO and President Steven Foster reported buying additional company stock in a private transaction. On November 14, 2025, he purchased 19,455 shares of common stock, increasing his direct holdings to 22,878 shares after the transaction. The purchase was part of a securities purchase agreement for a private investment in which each share of common stock was sold together with a warrant.

Along with the shares, Foster also acquired warrants to purchase up to 19,455 additional common shares. The combined purchase price for each share and accompanying warrant was $1.285, and the warrants have an exercise price of $1.16 per share and expire on November 14, 2028. These details show how a key executive has recently committed more capital to Tenon Medical through both stock and long-term warrants.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOSTER STEVEN M

(Last) (First) (Middle)

104 COOPER CT.

(Street)

LOS GATOS CA 95032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenon Medical, Inc. [ TNON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	11/14/2025		P		19,455	A	(1)	22,878	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Purchase Warrant	$1.16	11/14/2025		P		19,455		11/14/2025	11/14/2028	Common Stock	19,455	(1)	19,455	D

Explanation of Responses:

1. On November 10, 2025, the Issuer entered into a Securities Purchase Agreement for an at-the-market private investment in public equity transaction, in which the reporting person purchased 19,455 shares of common stock of the Issuer and warrants to purchase up to 19,455 shares of common stock of the Issuer. The purchase price for each share of common stock and accompanying warrant was $1.285. The offering closed on November 14, 2025.

	/s/ Steven Foster	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tenon Medical (TNON) report in this Form 4?

The filing reports that Steven Foster, Tenon Medical's CEO, President, and a Director, purchased 19,455 shares of common stock and related warrants in a private transaction that closed on November 14, 2025.

At what price did the Tenon Medical (TNON) CEO buy the new shares and warrants?

The purchase price was $1.285 for each share of Tenon Medical common stock together with an accompanying warrant to purchase one additional share.

How many Tenon Medical (TNON) shares does the reporting person own after this transaction?

Following the reported transaction, Steven Foster directly owns 22,878 shares of Tenon Medical common stock, as shown in the Form 4.

What are the key terms of the Tenon Medical (TNON) warrants acquired in this filing?

The warrants acquired allow the holder to purchase up to 19,455 common shares of Tenon Medical at an exercise price of $1.16 per share, exercisable through November 14, 2028.

What type of transaction did Tenon Medical (TNON) use for this insider purchase?

On November 10, 2025, Tenon Medical entered into a Securities Purchase Agreement for an at-the-market private investment in public equity transaction, under which Steven Foster bought the shares and warrants.

Who is the reporting person in this Tenon Medical (TNON) Form 4 and what is their role?

The reporting person is /s/ Steven Foster, who is identified as a Director and an Officer of Tenon Medical, serving as CEO and President.